SCHEMBL6358676

SCHEMBL6358676

CC(C)OB(OC(C)C)C(Cl)Cl

nearest known ligand 0.31

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.31
TSHR P16473 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL998407 0.72
SCHEMBL6840576 0.65
SCHEMBL9497606 0.65
SCHEMBL2128062 0.65
SCHEMBL38188 0.62
SCHEMBL17598891 0.62
SCHEMBL3261343 0.62
SCHEMBL10535002 0.60
Ammonia Solution, Strong SCHEMBL10617791 0.60
SCHEMBL564758 0.60

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119095984-A Sequencing methods using 3' allyl-terminated nucleotides 伊路米纳有限公司 2024-12-06 CN disclosed
US-20050118209-A1 Cosmetic or dermatological preparations for preventing damages to skin caused by peroxides BASF AKTIENGESELLSCHAFT (DE) 2005-06-02 US disclosed
US-6372883-B1 FOR THERAPY AND PROPHYLAXIS OF INFECTIONS CAUSED BY HEPATITIS C, HEPATITIS G AND HUMAN GB VIRUSES HOFFMANN-LA ROCHE INC. 2002-04-16 US disclosed
US-6018020-A VIRICIDES WHICH ARE PROTEASE INHIBITORS AGAINST HEPATITIS C AND HEPATITIS G HOFFMAN-LA ROCHE INC. (US) 2000-01-25 US disclosed
EP-0941233-A2 ANTIVIRAL PEPTIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 1999-09-15 EP disclosed
US-5866684-A Peptidyl inhibitors of viral proteases HOFFMANN-LA ROCHE INC. (US) 1999-02-02 US disclosed
US-5776902-A Boronophenyl analogs of phospholyrosines TRUSTEES OF TUFTS UNIVERSITY (US) 1998-07-07 US disclosed
WO-1998022496-A2 ANTIVIRAL PEPTIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 1998-05-28 WO disclosed
US-5580979-A Phosphotyrosine peptidomimetics for inhibiting SH2 domain interactions TRUSTEES OF TUFTS UNIVERSITY (US) 1996-12-03 US disclosed
WO-1995025118-A2 INHIBITORS OF SH2 DOMAIN INTERACTIONS TRUSTEES OF TUFTS UNIVERSITY (US) 1995-09-21 WO disclosed
US-4701545-A REACTING STERICALLY HINDERED BASE WITH MIXTURE OF DIHALOALKANE AND TRIALKYL BORATE WASHINGTON STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 1987-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050118209-A1 Cosmetic or dermatological preparations for preventing damages to skin caused by peroxides CAT, LPO, GPX4 ALDH1A1 184/4885TSHR 2428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.